Antimycobacterial activity of a new peptide Polydim-I isolated from neotropical social wasp Polybia dimorpha by Neves, Rogério Coutinho das et al.
RESEARCH ARTICLE
Antimycobacterial Activity of a New Peptide
Polydim-I Isolated from Neotropical Social
Wasp Polybia dimorpha
Rogerio Coutinho das Neves1, Monalisa Martins Trentini1, Juliana de Castro e Silva2,
Karina Smidt Simon3, Anamelia Lorenzetti Bocca3, Luciano Paulino Silva2, Marcia
Renata Mortari2, Andre Kipnis1, Ana Paula Junqueira-Kipnis1*
1 Department of Microbiology, Immunology, Parasitology and Pathology, Institute of Tropical Pathology and
Public Health, Federal University of Goiás, Goiânia, Brazil, 2 Laboratório de Toxinologia. Campus Darcy
Ribeiro, Instituto de Ciências Biológicas, Departamento de Ciências Fisiológicas, University of Brasilia,
Brasília, Brazil, 3 Depto Biologia Celular. Instituto de Biologia. Laboratório de Imunologia Aplicada,
University of Brasilia, Brasília, Brazil
* ana_kipnis@ufg.br
Abstract
Mycobacterium abscessus subsp.massiliense, a rapidly growing mycobacteria (RGM) that
is becoming increasingly important among human infectious diseases, is virulent and patho-
genic and presents intrinsic resistance to several antimicrobial drugs that might hamper
their elimination. Therefore, the identification of new drugs to improve the current treatment
or lower the risk of inducing resistance is urgently needed. Wasp venom primarily comprises
peptides that are responsible for most of the biological activities in this poison. Here, a novel
peptide Polydim-I, from Polybia dimorpha Neotropical wasp, was explored as an antimyco-
bacterial agent. Polydim-I provoked cell wall disruption and exhibited non-cytotoxicity
towards mammalian cells. Polydim-I treatment of macrophages infected with differentM.
abscessus subsp.massiliense strains reduced 40 to 50% of the bacterial load. Additionally,
the Polydim-I treatment of highly susceptible mice intravenously infected withM. abscessus
subsp.massiliense induced 0.8 to 1 log reduction of the bacterial load in the lungs, spleen,
and liver. In conclusion, this is the first study to show the therapeutic potential of a peptide
derived from wasp venom in treating mycobacteria infections. Polydim-I acts on theM.
abscessus subsp.massiliense cell wall and reduce 40–90% of the bacterial load both in
vitro and in vivo. The presented results encourage further studies on the use of Polydim-I as
one of the components forM. abscessus subsp.massiliense treatment.
Introduction
Mycobacterium abscessus subsp.massiliense is a rapid growing mycobacteria (RGM) that is
becoming increasingly important among human infectious diseases and is associated with soft
tissue infections that are caused by contaminated hospital equipment and solutions following
small invasive procedures or intramuscular injections [1, 2]. This group includes the formally
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knownMycobacterium massiliense [3, 4] that is virulent and pathogenic, inducing a chronic
and disseminated evolution in the host, independent of the immune status [3–7]. In Brazil,
2,000 new cases of RGM infections have been diagnosed since 1998, most of which occurred
following surgical procedures such as myopia correction, mesotherapic procedures, breast
implants, or esthetical procedures, usually associated with contaminated videoscopy equip-
ment and solutions. Among the RGM detected, most of these cases were infections withM.
abscessus subsp.massiliense [8, 9].
M. abscessus subsp.massiliense infection outbreaks might be a consequence of the intrinsic
resistance of these bacteria to 2% glutaraldehyde, a commonly used high-level disinfecting
solution [2]. The most appropriate treatment forM. abscessus subsp.massiliense infections is
to use a combination of drugs to avoid the development of resistance. Currently, the most com-
monly used chemotherapy includes the use of clarithromycin (CLR) together with amikacin
(AMK) [5], moxifloxacin (MXF) or cefoxitin (FOX) [6]. The major problem of chemotherapy,
in addition to intrinsic resistance, is the development of resistant strains that vary from 4.5%
resistance to CLR to 18% to FOX [10]. In addition, these drugs have hepatotoxic, enterotoxic,
nephrotoxic, hematotoxic and skin side effects when used for long periods of time, and these
side effects may result in non-adherence to therapy [11]. Consequently, new, improved and
efficient drugs against RGM are essential.
An interesting approach for the development of new drugs is the use of antimicrobial pep-
tides (AMP), also known as natural antibiotics. Interestingly, AMP can be administered indi-
vidually or in association with conventional chemotherapeutic drugs and have presented
promising results for treating several infectious diseases [12–14]. The mechanisms underlying
the activity of AMP actions seem to vary according to each family of molecules, but in general,
these activities rely on their ability to permeabilize biological membranes, create pores, or affect
intracellular activities [15].
Wasp venoms primarily comprise peptides, including AMP, which are responsible for most
of the biological activities of this poison. Among those peptides, the most recurrent are those
from the class of mastoparans [16–18], small cationic and amphiphilic alpha-helical peptides
that possess high affinity to negatively charged biological membranes. Thus, the venom of
social wasps has great potential for the study of new antimicrobials, particularly with respect to
antimycobacterial activity. Currently, countless peptides remain unknown because of a lack of
studies focusing on the identification of antimicrobial peptides from the venom of Neotropical
social wasps. Thus, the aim of this study was to investigate the effects of a novel peptide: Poly-
dim-I that was isolated from the venom of the Neotropical wasp Polybia dimorpha as a poten-
tial antimycobacterial agent.
Materials and Methods
Collection of specimens and venom extraction
Females of Polybia dimorpha were collected at Brasília, Distrito Federal, Brazil, under license in
accordance with the Normative Instruction No. 154, fromMarch 2007, of IBAMA (Brazilian
Institute of Environment and Renewable Natural Resources, license number 21723–1). More-
over, authorization of the Access and Remittance of the Brazilian genetic patrimony was
obtained from the CNPq (license number 010476/2013-0). The wasps were sacrificed after
freezing at -20°C. Following species identification (Prof. Fernando B. Noll, UNESP-SP), the
venom sacs were dissected and macerated in a 10% acetonitrile in deionized water solution and
centrifuged at 5000 × g for 10 min, at 4°C. The supernatant was carefully collected and submit-
ted to a filtration using an ultra-filter (Millipore) with a 3-kDa cut-off for 30 min at 5000 × g.
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The resultant ultrafiltrate, which was characterized by the presence of low molecular mass
compounds, was collected, lyophilized and weighed.
Peptide fractionation and purification
The filtered extract was resuspended in 2% acetonitrile in water (ACN/H2O) and 0.07% tri-
fluoroacetic acid (TFA). The solution was subjected to chromatography using a reversed-phase
high performance liquid chromatography (RP-HPLC) column (C18 ODS, Jupiter 15 μm,
20 × 250 mm, Phenomenex, Torrence, CA, USA) at a flow rate of 1.5 mL/min and was then
eluted using a linear gradient from 5% ACN/H2O (v/v) (containing 0.07% TFA) for 20 min,
followed by 5 to 60% for 40 min and under 60% for 20 min. The absorbance of the eluted com-
pounds was monitored at 214 and 280 nm, and the fractions were manually collected and sub-
sequently lyophilized.
MALDI-TOF mass spectrometry
The fractions containing Polydim-I were subjected to identification (purity and identity)
through matrix-assisted laser desorption/ionization mass spectrometry time-of flight (MAL-
DI-TOF TOF) (UltraFlex III, Bruker Daltonics, Germany) under reflector (MS) and LIFTTM
(MS/MS) positive modes. Prior to analysis, the fractions were dissolved in a saturated solution
of α-cyano-4-hydroxycinnamic acid matrix in acetonitrile/water/3% trifluoroacetic acid (5/4/
1). Additionally, the peptides’mass spectra and sequencing were manually interpreted using
the FlexAnalysis 3.0 software (Bruker Daltonics, Germany). The monoisotopic molecular mass
of the peptide was determined as the ratio between the m/z peaks in the spread profile (m/z
ratio from 600 to 3,000). Moreover, similarity searches were performed using Fasta3 programs,
the Expasy12 server and BLASTP13.
Polydim-I synthesis
The Polydim-I (a novel peptide derived from wasp Polybia dimorpha venon) was synthesized
through solid phase chromatography using an N-9-fluorophenylmethoxy-carbonyl (F-MOC)
strategy and purified through RP-HPLC at Aminotech Development and Technology. More-
over, the purity and sequence of the peptide were assessed using the same protocol described
for the identification of the natural peptide.
Bacterial strain preparation
M. abscessus subsp.massiliense isolates GO 01, GO 06, GO 07, GO 08, GO 13, and GO 18, were
randomly chosen from a collection bank of isolates from a Brazilian epidemic outbreak that
occurred in Goiânia, State of Goiás during 2005 and 2007 [5], and CRM0020 (M. abscessus
subsp.massiliense), and ATCC19977 (M. abscessus subsp. abscessus) reference strains were
included.M. abscessus subsp.massiliense were identified previously by colony morphology,
biochemical testes, PCR-Restriction-enzyme Analysis (PRA-hsp65), and partial rpoB gene
sequencing [5]. For the in vitro experiments, aliquots of frozen mycobacteria were grown in
Mueller Hinton (MH, HIMEDIA) with 0.05% Tween 80 at 35°C with agitation (200 × rpm) for
three days. The culture concentration was adjusted to a 0.5 scale of McFarland (approximately
1.5 × 108 CFU/mL) after vigorous homogenization to dissolve clumps.
For mice intravenous injection,M. abscessus subsp.massiliense GO 06, previously evaluated
in mice [19] with known concentration and maintained at -80°C were thawed and suspended
in phosphate-buffered saline (PBS), 0.05% Tween 80 to approximately 106 CFU/mL.
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AllM. abscessus subsp.massiliense suspensions were plated onto MH agar for CFU
determination.
Minimum inhibitory concentration test (MIC)
MIC was determined according to ATS/IDSA recommendations [20]. Bacterial cultures were
further adjusted, and 100 CFU was deposited into each well of a 96-well microplate that con-
tained serially diluted Polydim-I in levels ranging from 243.2 to 3.8 μg/ml. Lyophilized Poly-
dim-I was resuspended in 3% DMSO and further diluted in PBS before adding to the cultures.
The control wells received bacteria and PBS (growth control) or CLR at concentrations ranging
from 8 to 0.06 μg/mL (inhibition control). The plates were incubated for three days at 35°C.
The MIC (lowest concentration without bacterial growth) was estimated by CFU counting
after plating in MHmedia.
Scanning Electron Microscopy analysis of peptide effect onM.
abscessus subsp.massiliense
M. abscessus subsp.massiliense colonies grown on MH agar were removed from the plates and
exposed to 3.8 or 7.6 μg/mL of Polydim-I or 0.5 μg/mL of clarithromycin for 24 h. As a negative
control, the colonies were incubated with PBS alone. After incubation, the cells were fixed with
modified Karnovsky solution (paraformaldehyde 1% and glutaraldehyde 3% in 0.07 M cacody-
late buffer, pH 7.2) for 30 min at 4°C. The fixative solution was subsequently removed, and the
samples were dehydrated through increasing concentrations of ethanol solution (30%, 50%,
70%, 90%, and 100%) for 10 min, followed by acetone and hexamethyldisilazane (HMDS) (V/
V) for an additional 5 min. The final dehydration step was performed with HMDS for 5 min.
After the samples were completely dry, a thin layer of gold was deposited using a Denton Vac-
uum Desk V apparatus. The images were obtained using a Jeol JSM – 6610 microscope (Jeol,
Japan) equipped with energy dispersive spectroscopy—EDS (Thermo scientific NSS Spectral
Imaging).
Animals
BALB/c and IFN-γKO (Knockout) mice were obtained from the Instituto de Patologia Tropical
e Saúde Pública from Federal University of Goiás animal facilities. All animals were housed
according to the Colegio Brasileiro de experimentação animal (COBEA) under the supervision
of a Veterinarian. Female mice that were 6–8 weeks old and weighed 22–25 g from both line-
ages were used. Five groups of 6 animals (IFN-γKO) each were maintained in a HEPA filtered
rack with water and food available ad libitum. To enrich the animal environment, cardboard
tubes were weekly added to the cages for the 28–30 days duration of the study. Ten BALB/c
mice that were maintained under the same conditions were used to obtain macrophages. All
protocols were submitted and approved through the Comitê de Ética no Uso de Animais em
Pesquisa-UFG (Protocol: 027/14). All experiments were repeated three times, and a total of 10
BALB/c and 90 IFN-γKOmice were used.
Peritoneal macrophages cultures
BALB/c mice were injected with thioglycolate 72h before the peritoneal macrophages were col-
lected. The macrophages (1 × 106 cells/ml), which were diluted in RPMI-1640 (Sigma,
St. Louis, USA) supplemented with penicillin/streptomycin (100 U/mL, 100 g/mL), 2 mM L-
glutamine, 2 mM non-essential amino acids, 1 mM sodium pyruvate (all reagents from Sigma-
Aldrich, St Louis, MO, USA) and 10% fetal bovine serum (FBS), were incubated for 24 h at
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37°C, 5% CO2, in 24-well microplates containing 18-mm circular cover slides or in 96 well
microplates. Peritoneal macrophages plated in 24-well microplate were used to evaluate the
morphology/viability after Polydim-I treatment of infected macrophages. The peritoneal mac-
rophages plated in 96 wells plates were used to address the microbicidal effects of Polydim-I on
infected macrophages (see details bellow).
J774 macrophage cytotoxicity evaluation
Cytotoxic activity was measured using J774 macrophages cells treated with 7.6, 15.2, 60.8, and
121.6 μg/mL of the peptide for 24 h under the same conditions as described for peritoneal mac-
rophages. The percentage of cytotoxicity of Polydim-I was evaluated by lactate dehydrogenase
(LDH) release assay using Cyto Tox 96 kit (Promega).
Hemolysis
A solution of fresh human red blood cells was used to test the hemolytic capacity of the peptide
at levels ranging from 7.6 to 121.6 μg/mL. Fifty micro liters of a 3% cell suspension of EDTA
treated blood obtained from healthy volunteers were added to a 96 well microplate. Different
concentrations of the peptide (v/v) were added to each well and after one hour incubation, the
microplates were centrifuged, and the supernatant was carefully collected and read at 540 nm
using an ELISA microplate reader (Thermo Labsystems, USA). As positive lysis control the
erythrocytes were incubated with water. The percentage of hemolysis from each test was calcu-
lated relative to the positive control. Blood were collected from healthy individuals that signed
a written Informed Consent. The procedures and the informed consent were approved by the
Ethics Committe on Human Research of Faculty of Medicine/University of Brasilia (UNB).
Mycobactericidal activity of Polydim-I on infected macrophages
Peritoneal macrophages that were obtained as described above were infected withM. abscessus
subsp.massiliense (MOI 10:1) for three hours. Subsequently, the cultures were washed three
times with warm RPMI. The obtained supernatants from the washes were pooled and plated
onto MH agar for CFU determination. The infected macrophages were treated with Polydim-I
at 7.6 μg/mL in 200 μL of RPMI. After three days of incubation, the supernatant was removed,
the cells were washed three times with warm PBS to remove extra cellular bacteria and the cells
were lysed with water. The resulting lysate and supernatant were spread onto MH agar for
CFU determination. To estimate the number of bacteria phagocytosed by macrophages prior
to Polydim-I treatment, the number of CFU obtained from the pooled supernatant after three
hours of infection was subtracted from the total inoculum (106). Additionally, infected perito-
neal macrophages were cultivated in 24 well plate containing circular cover slides to investigate
the cell morphology. Three independent experiments were performed. Additionally, two exper-
iments were performed using non-activated peritoneal macrophages to confirm Polydim-I bac-
tericidal activity.
The cover slides from the 24-well microplates were washed with PBS and fixed with metha-
nol for 5 min. Then, the slides were stained with Instant Prov (Newprov, Pinhais, Brazil) and
attached to glass slides using Entellan (Merck, Darmstadt, Germany), and photomicrographs
(400 ×) were captured using light microscopy (Carl Zeiss, Oberkochen, Germany).
Infection of IFN-γKOmice withM. abscessus subsp.massiliense
The animals were intraperitoneously anaesthetized with a mixture of 70mg/kg of ketamine and
7mg/kg of xylazine followed by intravenous infection in the retro-orbital plexus with 106 CFU
Polydim ControlsM. abscessus subsp.massilienseGrowth
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ofM. abscessus subsp.massiliense GO 06. The bacteria load in the mice organs was monitored
at days 1 and 18 post infection. At day one post infection, one animal from each treatment
group (total of 6 animals) was euthanized to determine the efficiency of the infection. The ani-
mals were routinely (twice daily) inspected for mortality during 18 days. Animal health was
monitored for the following signs: loss of appetite, dehydration, prostration or lethargy. A
humane endpoint protocol to perform euthanasia of animals presenting any of the above
symptoms was approved the Ethical Committee on the animal use of Universidade Federal of
Goiás. None of the animals presented any of the above signs or died during the experiments.
Eighteen days after infection, the lungs, liver and spleen from one animal of each treatment
group were homogenized in PBS containing 0.05% of Tween 80, and the bacterial load of the
organs was determined as previously described [19]. Briefly, the lungs, liver and spleen were
homogenized in 5 mL of PBS with 0.05% of Tween 80. The organ homogenates were serially
diluted in PBS/Tween 80, plated onto MH agar plates and incubated for 7 days at 35°C. The
colonies grown on MH agar plates were counted, and the bacterial load in each organ was
determined after correcting the values based on dilution, plating volume, and the volume of
homogenates.
Treatment of IFN-γKOmice infected withM. abscessus subsp.
massiliense
The Polydim-I treatment scheme forM. abscessus subsp. massiliense was performed accord-
ing to [21] with some modifications. Briefly, anesthetized IFN-γKO mice were intrave-
nously infected withM. abscessus subsp. massiliense (106 CFU/mL). Prior to treatment, the
animals were individually weighed, and the mean live weight (mLW) was used to calculate
the treatment dose. After 18 days of infection, the animals (4 animals/group) were treated
once a day intraperitoneally for eight days. During the treatment, the animals were moni-
tored for signs of sickness as state above. For the Polydim-I treatment, three groups received
the following dose treatments: 2 mg/kg/mLW, 1 mg/kg/mLW, and 0.5 mg/kg/mLW [2, 22].
As controls, a group was treated with CLR (200 mg/kg/mLW, treatment control) and
another group received PBS (infection control). None of the animals became clinically ill
or died during the experiments. To minimize pain and distress the animals were quickly
handled by trained researchers. All animals were humanely euthanized by cervical disloca-
tion by a veterinarian, one day after the end of the treatments, and the spleen, lungs and
liver were collected separately and frozen for CFU determination. The experiments were
repeated three times.
Histopathological analysis
Twenty six days after intravenous infection, the right caudal lung lobes were removed and
fixed in 10% buffered formaldehyde. To evaluate in vivo acute cytotoxicity effect of Polydim I,
BALB/c mice treated with 2 or 20 mg/kg/mLW and the livers were analyzed 48 hours later.
Five micrometers thick slices were stained with Hematoxilin and Eosin (H.E.) and analyzed
with light microscopy (Leica DM/LS IV 500 microscopy system), and images were processed
with LAS software version 4.4 (Leica). A certified Pathologist blinded to original section
sources evaluated the slides. Scores were determined based on the area with lesions relative to
the area of the total visual field using AxioVision microscopy Software. The results are pre-
sented as the percentage of area with lesions. Three different fields were evaluated per slide for
each animal from each group.
Polydim ControlsM. abscessus subsp.massilienseGrowth
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Statistical analysis
The experimental data were tabulated and grouped using the Microsoft Excel 2010 software
and exported to the Graph Pad Prism 5.0 software (Graph Pad Software, San Diego CA, USA)
for statistical analysis. The results were compared using one-way ANOVA, followed by Dunn’s
test. p-values less than 0.05 were considered statistically significant. Data are available as online
files (S1–S4 Figs).
Results
Separation, identification and synthesis of Polydim-I
A total of 684 venom glands were obtained from a single nest of Polybia dimorpha and pro-
vided 21.4 mg of ultrafiltered crude venom (compounds with molecular masses lower than
3,000 Da). The obtained RP-HPLC profile comprised 13 fractions (Fig 1A), which were termed
Poly 1–13. Two chromatographic procedures with injections of 200 μL each were performed,
and both profiles showed the same fraction elution pattern. Polydim-I corresponded to fraction
Poly 12, eluted at a retention time of approximately 62 min at 60% of ACN as indicated in
Fig 1A.
Fraction 12 had a major molecular component at m/z 2441.7 [M+H]+ based on the mass
spectrometry analysis, and this peptide was named Polydim-I (Fig 1B). De novo sequencing of
the fragmented ion through MS/MS resulted in a sequence of 22 amino acid residues (AVA-
GEKLWLLPHLLKMLLTPTP), as shown in Fig 1C.
Thus, Polydim-I was synthesized at Aminotech Development and Technology LTDA. The
purity (> 99%) and the correct sequence of the peptide were verified and confirmed through
mass spectrometry upon receipt using the same parameters that were used for the natural
compound.
In vitro antimycobacterial and morphology modification activities of
Polydim-I againstM. abscessus subsp.massiliense
The Polydim-I antimycobacterial activity was evaluated against six isolates ofM. abscessus
subsp.massiliense from an epidemic outbreak and two reference strains resulting in a MIC of
60.8 μg/mL, while treatment at a concentration of 15.2 μg/mL inhibited 55 to 68% ofM. absces-
sus subsp.massiliense strains growth (data not shown). To determine whether the mycobacteri-
cidal effect of Polydim-I could influence the shape of the cell envelope, scanning electron
microscopy (SEM) ofM. abscessus subsp.massiliense GO 06 exposed to the peptide was per-
formed. As shown in Fig 2, the cellular shape and cell wall integrity were slightly affected when
the mycobacteria were exposed to 7.6 μg/mL of the peptide (Fig 2B, arrow heads). The cell
shape was expressively damaged when the concentration of the peptide was 15.2 μg/mL (a rep-
resentative damaged area is shown in Fig 2C). The exposure ofM. abscessus subsp.massiliense
to the antibiotic CLR, which prevents bacterial growth through the inhibition of protein syn-
thesis, did not result in visible morphological changes (Fig 2D). Taken together, the SEM data
suggest that Polydim-I might elicit deleterious effects through perturbations of the cell
integrity.
Polydim-I displays bactericidal activity on intracellular environment
To further investigate whether a combination of mycobacteria infection and peptide treatment
could affect the membrane integrity of peritoneal macrophages, these cells were infected with
six differentM. abscessus subsp.massiliense isolates or the reference strains CRM0020 and
ATCC19977 (at MOI 10:1) and treated with 7.6 μg/mL of Polydim-I. All tested strains behaved
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PLOS ONE | DOI:10.1371/journal.pone.0149729 March 1, 2016 7 / 21
similarly, and as shown in S5A Fig (control) and S5B (treated), the peptide treatment of perito-
neal macrophages apparently did not affect the cell morphology, which was not altered after
infection with the representativeM. abscessus subsp.massiliense isolate GO 06 shown in S5C
and S5D Fig. The macrophage morphology suggests that they were viable throughout the
experiments. Additionally, CFU counting of infected and Polydim-I treated macrophages
showed a significant reduction in the bacterial load when compared to the infected non-treated
Fig 1. Chromatographic profile, mass spectra and de novo sequencing of Polydim-I peptide. (A).
Chromatographic profile obtained after separation of the low molecular weight compounds from Polybia
dimorpha venom through reversed phase high performance liquid chromatography. The fraction containing
the peptide Polydim-I is signalized. (B) Mass spectra of fraction 12 obtained through MALDI TOF/TOF, with
the major ion m/z 2441.7 [M+H]+. (C). De novo sequencing of Polydim-I using MS/MS. The ion series y is
written above with the 22 amino acids represented by letters.
doi:10.1371/journal.pone.0149729.g001
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macrophages (40 to 50% range; Figs 3 and 4). Infected macrophages treated with 1μg/ml of
CLR reduced 57–70% the bacterial load among the different tested strains (Fig 4).
As reasoned above, Polydim-I activity might be associated with the disruption of cell mem-
brane integrity. Nonetheless, to be a potential candidate as an antimicrobial agent, this com-
pound must show selective toxicity (12). Consequently, we analyzed whether Polydim-I
interferes with eukaryotic cell membranes using J774 macrophage cell line treated with 7.6,
15.2, 60.8, and 121.6 μg/mL of Polydim-I for 24 hours using LDH release assay. Polydim-I
started to present cytotoxicity on J774 cells at concentrations above 121.6 μg/mL (10%) (Fig
5A). However the Polydim-I peptide at concentrations up to 121.6 μg/mL presented less than
2.5% of hemolytic activity (Fig 5B).
In vivo anti-mycobacterial activity of Polydim-I
We have previously shown that BALB/c or C57BL/6 intravenous infection withM. abscessus
subsp.massiliense strain GO 06 (106 CFU) provided an adequate model of infection with the
bacterial load maintained until 30 days post infection [19]. To optimize the analysis of the pep-
tide treatment effect in vivo, IFN-γKOmice, that have increased susceptibility to mycobacterial
infection, were infected withM. abscessus subsp.massiliense. Eighteen days post infection,
these animals were treated for 8 days with CLR (200 mg/kg/mLW) or one of three different
doses of Polydim-I (2, 1 or 0.5 mg/kg/mLW) for 8 days. Fig 6 shows the CFU obtained after 28
days post infection withM. abscessus subsp.massiliense and the different treatment schemes.
As shown, Polydim-I treatment at 2 mg/kg/mLW showed significant reduction of the bacterial
load in all analyzed organs. The peptide treatment at this concentration reduced the bacillary
load of the susceptible animals by up to 90% in the lungs and spleen (Fig 7). In addition, Poly-
dim-I treatment of mice infected withM. abscessus subsp.massiliense reduced the inflamma-
tory response caused by the infection as determined by the quantification of the area occupied
by lesion/inflammatory responses (Fig 8). The highest dose of Polydim-I used to treat infected
Fig 2. Morphology ofM. abscessus subsp.massiliense cell surface upon the action of Polydim-I
peptide. (A) Scanning Electron microscopy of untreatedM. abscessus subsp.massiliense cells. (B)M.
abscessus subsp.massiliense exposed to 3.8 μg/mL of Polydim-I peptide for 24 hours, presenting mild
surface alterations (white arrows).M. abscessus subsp.massiliense with severe cell wall disruptions after
treatment with 7.6 μg/mL of Polydim-I peptide for 24 hours (C). (D)M. abscessus subsp.massiliense treated
with clarithromycin (0.5 μg/mL) without visible cell wall damage. (A) and (C) 10,000 × magnification. (B) and
(D) 12,000 × magnification.
doi:10.1371/journal.pone.0149729.g002
Polydim ControlsM. abscessus subsp.massilienseGrowth
PLOS ONE | DOI:10.1371/journal.pone.0149729 March 1, 2016 9 / 21
Fig 3. M. abscessus subsp.massiliense CFU in infectedmacrophages treated with Polydim-I peptide. Peritoneal macrophages from BALB/c mice
were infected with 6 isolates ofM. abscessus subsp.massiliense (A thru F) or the reference strains CRM0020 (G) and ATCC19977 (H) at a MOI of 10:1, and
treated with 7.6 μg/mL of Polydim-I peptide or with 1 μg/mL of clarithromycin. Bacterial load of phagocytosed bacteria were determined at three hours after
infection and total recovered bacteria from supernatant and macrophages at 72 hours after infection were determined for non-treated (closed circles), peptide
treated (closed squares), and clarithromycin treated (open circles). The data represent mean of quadruplicates and is representative of three independent
experiments. One-way ANOVA followed by Dunn’s test was used to determine significant differences (* p<0.05).
doi:10.1371/journal.pone.0149729.g003
Polydim ControlsM. abscessus subsp.massilienseGrowth
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mice did not show damages associated with cytotoxicity in the lungs or liver (Data not shown
and S6 Fig).
Discussion
M. abscessus subsp.massiliense presents resistance to several of the conventional treatment reg-
imens that are typically used to treatM. tuberculosis. Therefore, the identification of new drugs
to improve the current treatment or lower the risk of inducing resistance is urgently needed. In
this context, the present work shows the first use of a peptide derived from wasp venom that
possesses mycobactericidal activity. Polydim-I provoked cell wall disruption and presented low
cytotoxicity towards mammalian cells. The treatment ofM. abscessus subsp.massiliense-
infected macrophages with the peptide reduced approximately 50% of the bacterial load. Addi-
tionally, Polydim-I treatment of highly susceptible mice infected withM. abscessus subsp.mas-
siliense induced a reduction of the bacterial load in the lungs, spleen, and livers.
Polydim-I, which was a peptide, isolated from the venom of Polybia dimorpha, presents
characteristics similar to other wasp AMPs (Fig 1), with a structure comprising a series of
hydrophobic amino acid residues, such as methionine, leucine, valine, and proline, which are
intercalated with negatively charged residues to create an amphipathic surface [23, 24]. How-
ever, due to the intrinsic characteristics observed in the sequence of this peptide, it cannot be
classified as mastoparan and has subsequently emerged as a new class of peptides within the
major group of AMPs. Some peptides isolated from other wasps, such as MP-AF and MPI,
exhibit interesting antimicrobial activity against Gram-positive and Gram-negative bacteria
[25] as well as antifungal activity against Candida albicans and Candida glabrata yeasts [26].
Natural peptides, such as RR-11, a cationic host defensin, have been demonstrated to have
activity againstM. smegmatis [27] when used at a concentration of 125 μg/mL. Our findings
are promising, as using a much lower concentration of peptide (7.6 μg/mL) achieved a 50%
reduction of mycobacterial growth. Although we have included in our experiments Tween 80
Fig 4. Percentage of mycobacterial load reduction in infectedmacrophages by Polydim-I treatment.
The CFU in peritoneal macrophages, 72 hours after treatment with Polydim-I (white bars) or clarithromycin
(black bars), was determined and the percentage of inhibition was calculated in relation to non-treated
macrophage cultures. The data represent mean of quadruplicates and is representative of three independent
experiments. One-way ANOVA followed by Dunn’s test was used to determine significant differences (*
p<0.05).
doi:10.1371/journal.pone.0149729.g004
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Fig 5. J774macrophage cell line cytotoxic effects and hemolytic activity of Polydim-I peptide. J774
macrophages were exposed to different concentrations of Polydim-I peptide (7.6, 15.2, 60.8, or 121.6 μg/mL)
for 3 days. Cell viability percentage was determined by LDH release assay (A). In (B), the percentage of
human red blood cells lysis. The results represent three independent experiments.
doi:10.1371/journal.pone.0149729.g005
Polydim ControlsM. abscessus subsp.massilienseGrowth
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Fig 6. M. abscessus subsp.massiliense bacillary load reduction in IFN-γKO-infected mice after
treatment with Polydim-I peptide. IFN-γKOmice were infected intravenously with 106 CFU ofM. abscessus
subsp.massiliense strain GO 06. Eighteen days after infection, the mice were treated with 2 mg/kg/mLW of
Polydim ControlsM. abscessus subsp.massilienseGrowth
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to avoid clumping, a factor that has been shown to disrupt mycobacteria cell wall integrity
before [28], we believe that that inhibitory effect is mainly due to the peptide because all con-
trols also were grown with the detergent.
The treatment ofM. abscessus subsp.massiliense with Polydim-I disrupted the bacteria cell
envelope (Fig 2); a similar phenomenon was observed when Candida sp. [26] were treated with
the wasp MPI peptide, which caused cell wall disruptions. Defensin RR-11 also promotedM.
smegmatis cell wall destruction [29]. LL-37, a cathelicidin that is secreted from macrophages,
exhibited anti-mycobacterial activity, further strengthening the potential use of these agents
against mycobacteria [30]. In a recent review, Padhi and colleagues suggested that the mecha-
nism of action of natural peptides showing activity against mycobacteria involves the destruc-
tion of cell envelope structures and/or functions through associations with lipoarabinomannan
[30, 31]. Additionally, bacterial membranes have unique lipids such as phosphatidylglycerol,
cardiolipin or phosphatidelserine conferring a negative charge that may favor AMP association
[25]. Thus, the activity of Polydim-I is likely associated with cell envelope or cell wall damage
because this effect was primarily observed with other microorganisms [25, 26], but further
studies in this field are needed.
Macrophages are the main targets of mycobacteria and are morphologically and function-
ally well characterized; hence, these cells were used in cytotoxicity assays (J774 macrophages)
and to evaluate in vitro Polydim-I action againstM. abscessus subsp.massiliense phagocytosed
by macrophages. The membrane and cell envelope interference properties of natural peptides
could affect eukaryotic cells [32], but the peptide used in the present study did not exhibit any
expressive interaction or destruction of eukaryotic cell membranes at concentrations60.8 μg/
mL. Natural peptides such as cathelicidin also presented selective toxicity to mycobacteria
without damaging macrophage membranes [33], and this might be associated with the choles-
terol and other lipid contents of eukaryotic membranes [31]. In addition, cationic AMPs inter-
act with negatively charged membranes, such as seen among bacteria and tumoral cells [34, 35]
forming pores, a role most likely performed by the arginine amino acid residues present in the
peptides [34]. In contrast, the membranes of normal eukaryotic cells have a predominant neu-
tral charge and consequently could be resistant to the AMPs action. The results of our research
describes for the first time, a peptide isolated from the venom of wasps with activity against
mycobacteria and although it presented some in vitro cytotoxicity, it can be further modified to
improve its efficacy (reduce cytotoxicity and increase mycobactericidal activity). The in vivo
selective action presented by Polydim-I could be due to the presence of two arginine residues
present in its N-terminus. These results are promising because for other wasp AMPs, particu-
larly mastoparans such as MP-AF, MP-A, MP-B, MP-D, MP-M, and MP-V, high cell toxicity
through hemolysis was observed [24]; however, the results obtained in the present study
showed a low level of hemolysis.
Treatment of infected macrophages with 7.6 μg/mL of Polydim-I decreased approximately
50% of the bacterial load. Although few studies have used infected macrophages to test new
drugs against mycobacteria [36], no scientific publication, to our knowledge, has examined
new drugs using macrophages that were infected withM. abscessus subsp.massiliensi, previ-
ously known asM.massiliense [4]. We hypothesize that an efficient drug will need to penetrate
Polydim-I (▲), 1 mg/kg/mLW of Polydim-I (▼), 0.5 mg/kg/mLW (■) of Polydim-I, or with 200 mg/kg/mLW of
clarithromycin (CLR, ). As control, a group of infected mice were treated with PBS (●). The bacillary loads in
the lungs (A), spleen (B) and liver (C) were determined after euthanizing the mice at days 1, 18 and 26 post
infection. The data represent mean of four mice per group and is representative of three independent
experiments. One-way ANOVA followed by Dunn’s test was used to determine significant differences.
Statistically significant difference when compared to PBS treated control group (* p<0.05).
doi:10.1371/journal.pone.0149729.g006
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Fig 7. M. abscessus subsp.massiliense bacillary load reduction in IFN-γKO-infected mice after
treatment with Polydim-I peptide. IFN-γKOmice were infected intravenously with 106 CFU ofM. abscessus
subsp.massiliense. Eighteen days after infection, the mice were treated with Polydim-I peptide at three
Polydim ControlsM. abscessus subsp.massilienseGrowth
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granuloma and should not be eliminated through efflux pumps [37] in order to eliminate the
mycobacteria within the infected macrophages [36]. Therefore, infected macrophages are also
an effective model to evaluate the mechanism of action of antimycobacterial drugs.
Because this is the first study evaluating the treatment of mice infected withM. abscessus
subsp.massiliense, we used the mouse model of Lenaerts and colleagues [21] to test drugs
againstM. tuberculosis. IFN-γKOmice are highly susceptible to mycobacteria infections [38],
particularly infections withM. abscessus subsp.massiliense [7], which facilitates a more rapid
treatment result. Additionally, we used parenteral drug treatments in order to guarantee homo-
geneous bioavailability for all drugs as proposed before [22, 23]. The treatment of IFN-γKO
mice infected withM. abscessus subsp.massiliense using 2 mg/kg/mLW of Polydim-I substan-
tially reduced the bacterial load in the lungs, spleen and livers (Figs 6 and 7). Importantly,
when clarithromycin was used, theM. abscessus subsp.massiliense was not cleared from IFN-
γKO-infected mice; this finding indicates that, as observed with human RGM infection, a mul-
tidrug therapy is always needed to avoid bacterial persistence and possibly drug resistance
development [39, 40]. The results obtained in the present study are consistent with those
obtained for several drugs that have been demonstrated as useful for treating mycobacterial
different dosages (2, 1 or 0.5 mg/kg/mLW) or with clarithromycin (CLR 200 mg/kg/mLW). As a control group,
infected mice were treated with PBS. Percentages of bacterial load reduction in the lungs (A), spleen (B) and
liver (C) from each treatment group were determined relative to the control PBS group (* p<0.05).
doi:10.1371/journal.pone.0149729.g007
Fig 8. Lung inflammatory lesions caused byM. abscessus subsp.massiliense infection were reduced by Polydim-I peptide treatment. Twenty-six
days after the challenge, the lungs were processed, sectioned, HE stained, and examined at 40 × or 100 × magnification. (A and B) normal lungs from PBS
treated control group at 40 × and 100 × magnifications, respectively; inflammatory lesions observed in the lungs of the infected group 40 × (C) and 100 × (D).
Lungs from animals infected and treated with Polydim-I (2 mg/kg/mLW) 40 × (E) and 100 × (F). The area of the inflammatory lesions were calculated and
plotted in a graph (G). One-way ANOVA followed by Dunn’s test was used to determine significant differences (* p<0.05).
doi:10.1371/journal.pone.0149729.g008
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infections [36, 41]. It will be interesting to evaluate the effect of Polydim-I treatment combined
with other drugs.
Lungs from animals infected withM. abscessus subsp.massiliense and treated with Poly-
dim-I showed less inflammatory lesions than the lungs from infected animals. Although, no
work have used IFNγ-KO to test new drugs to treatM. abscessus subsp.massiliense infection,
others have shown that depending on the peptide used, the bacterial load reduction is accom-
panied or not by reduction of the inflammatory lesions induced byM. tuberculosis infection
[29, 42]. It is interesting to note that the treatment with Polydim-I using doses ranging from 10
to 40 μg per animal, doses bellow the MIC, were sufficient to reduce approximately one Log of
the bacterial burden. Other authors have shown that AMP activate macrophages enhancing
their bactericidal activity as well as cytokine production [14, 43, 44]. Here we hypothesize that
Polydim-I might activate the infected macrophages potentiating the mycobacteria clearance.
M. abscessus subsp.massiliense is susceptible to parenteral drugs (amikacin, cefoxitin, and
imipenem) and oral macrolides (clarithromycin and azithromycin). Consequently, the ATS/
IDSA (American Thoracic Society/Infectious Disease Society of America) recommends that at
least two parental drugs and one oral drug should be used to treat infections to avoid drug
resistance development [20]. These drugs cause several collateral effects, such as gastric intesti-
nal dysfunction, ototoxicity, and neurotoxicity [45], and the use of clarithromycin has been
associated with a significantly increased risk of cardiac death [46]. Novel drugs, which target
different structures compared with most of the commercially available drugs, could be incorpo-
rated into multi-regimen treatments, thereby reducing the dosage and/or number of drugs
used and consequently lowering the risk of developing side effects. Therefore, Polydim-I could
improve the treatment ofM. abscessus subsp.massiliense infections because of the lower risk of
resistance development and the lower cost of production.
Some important aspects about the use of AMPs in general should be pointed out as for
example they could be degraded faster than other anti-microbial agents due to the action of tis-
sue peptidases/proteinases in vivo. Additionally, peptides could combine to host proteins and
generate specific humoral immune responses that could impair repetitive use of the peptide
[47–49].
In conclusion, this study was the first to demonstrate the therapeutic potential of a peptide
derived from wasp venom to treat mycobacteria infections. Polydim-I acts on theM. abscessus
subsp.massiliense cell wall and reduced the bacterial load both in vitro and in vivo. These
results encourage further studies on the use of Polydim-I and its derivative peptides as a com-
ponent in theM. abscessus subsp.massiliense infection treatment formulation.
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S5 Fig. Macrophage morphology after Polydim-I treatment and infection. Instant-Prov stain-
ing of: (A) Untreated macrophages; (B) Polydim-I peptide-treated macrophages; (C) macro-
phages infected withMycobacterium abscessus subsp.massiliense isolate GO 06 (MOI 10:1);
and (D) macrophages infected withM. abscessus subsp.massiliense isolate GO 06 and treated
with Polydim-I peptide.
(TIF)
S6 Fig. Histological analyses of the liver from mice treated with Polydim-I. BALB/c mice
were treated with 2 mg/kg/mLW (C and D) or 20 mg/kg/mLW (E and F) and 48 hours later
the livers were processed and stained with HE. As controls, mice were treated with PBS (A and
B). The results are presented at 40 x and 100 x magnification.
(TIF)
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